FDA Nixes United Therapeutics Petition on Tyvaso-Referencing Combination Products

Drug Industry Daily
A A
The FDA denied a United Therapeutics petition urging the agency to reject ANDAs for combination products referencing the company’s hypertension drug Tyvaso (treprostinil).

To View This Article:

Login

Subscribe To Drug Industry Daily